Non-myeloablative regimen consisting of busulfan, fludarabine, and ATG for allogeneic peripheral blood stem cell transplantation.

被引：0
|
作者：
Mayer, J [1 ]
Koristek, Z [1 ]
Krahulová, M [1 ]
Vorlicek, J [1 ]
机构：
[1] Masaryk Univ Hosp, Brno, Czech Republic
来源：
EXPERIMENTAL HEMATOLOGY | 1999年 / 27卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
361
引用
收藏
页码：131 / 131
页数：1
相关论文
共 50 条
  • [21] Non-myeloablative conditioning regimen in Allogeneic Peripheral Blood Stem Cell Transplantation (AlloPBSCT) for high-risk Hematologic Malignancies (HM)
    Vaz, CP
    Campilho, F
    Campos, A
    Carvalhais, A
    Roncon, S
    Martinho, A
    Duarte, R
    Raimundo, A
    Avila, A
    Pimentel, P
    BONE MARROW TRANSPLANTATION, 2001, 27 : S293 - S293
  • [22] Donor erythroid chimerism in mice after non-myeloablative allogeneic stem cell transplantation.
    Iannone, R
    Luznik, L
    Engstrom, LW
    Fuchs, EJ
    BLOOD, 1999, 94 (10) : 320B - 321B
  • [23] Allogeneic hematopoietic stem cell transplantation for Pesaro IIIβ-thalassemia major using fludarabine-based myeloablative or non-myeloablative conditioning regimen.
    Zhu, KG
    Gu, J
    Zhang, T
    Zhong, J
    BLOOD, 2005, 106 (11) : 35B - 35B
  • [24] Large granular lymphocyte (CD3+) leukemia developing after non-myeloablative allogeneic peripheral blood stem cell transplantation.
    Bair, AK
    Coyle, TE
    Gentile, TC
    BLOOD, 2002, 100 (11) : 453B - 453B
  • [25] Non-myeloablative stem cell transplantation - High stem cell dose will not compensate for T cell depletion in allogeneic non-myeloablative stem cell transplantation
    Passweg, JR
    Meyer-Monard, S
    Gregor, M
    Favre, G
    Heim, D
    Ebnoether, M
    Tichelli, A
    Gratwohl, A
    BONE MARROW TRANSPLANTATION, 2002, 30 (05) : 267 - 271
  • [26] Fludarabine - Oral busulfan myeloablative conditioning for allogenic peripheral stem cell transplantation. A single center experience in Colombia
    Rosales, C.
    Abello, V.
    Rosales, E.
    Esguerra, H.
    Linares, A.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (02) : 97 - 97
  • [27] Pseudothrombocytopenia after allogeneic non-myeloablative stem cell transplantation
    Gillis, S
    Eisenberg, ME
    Shapira, MY
    Or, R
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2003, 5 (09): : 671 - 673
  • [28] Non-myeloablative conditioning regimen for allogeneic stem cell transplantation in patients with advanced hematological malignancies
    Malesevic, M
    Stamatovic, D
    Tukic, L
    Marjanovic, S
    Balint, B
    Tarabar, O
    Todoric, B
    Ristic, L
    Milicevic, S
    BONE MARROW TRANSPLANTATION, 2001, 27 : S294 - S295
  • [29] A non-myeloablative regimen of fludarabine and melphalan is safe and well tolerated for allogeneic transplantation in multiple myeloma
    Qazilbash, Muzaffar H.
    Saliba, Rima M.
    Parikh, Gaurav C.
    Hosing, Chitra
    Mendoza, Floralyn
    Weber, Donna M.
    Wang, Michael
    Thomas, Sheeba K.
    Flosser, Thuy S.
    Kebriaei, Partow
    Popat, Uday
    Alousi, Amin M.
    De Lima, Marcos
    Champlin, Richard E.
    Giralt, Sergio A.
    BLOOD, 2007, 110 (11) : 890A - 890A
  • [30] Allogeneic haematopoietic stem cell transplantation after reduced-intensity regimen containing fludarabine, busulfan, and ATG (Fresenius)
    Brychtova, Y
    Doubek, M
    Mayer, J
    Krejci, M
    Koristek, Z
    Buchtova, I
    BONE MARROW TRANSPLANTATION, 2005, 35 : S209 - S209
12345